Sunday, September 6

Browsing: PostCDK46

Diagnosis

Capivasertib and Emerging Options in the Post–CDK4/6 Inhibitor Setting

By NewsCancerSeptember 1, 20260

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, closes with the competitive landscape around capivasertib plus fulvestrant in hormone…

Support

By NewsCancerAugust 28, 20260

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, opens a discussion of the treatment landscape for hormone receptor positive,…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.